How to Select the Right Preclinical Model for Drug Development

Despite decades of progress, drug development is still a high-risk endeavor. More than 90% of medication candidates fail clinical trials, most commonly due to a lack of efficacy or unexpected safety difficulties. The low predictive potential of preclinical models contributes significantly to this high attrition rate.

Preclinical model selection is therefore more than just a technical phase; it is a strategic decision that has a direct impact on translational success. Models that fail to effectively represent human disease biology can result in inaccurate data, squandered resources, and postponed timeframes.

This article presents a realistic, evidence-based paradigm for preclinical model selection that incorporates recent ideas from translational science, developing model systems, and model-informed drug development approaches.

Why do preclinical models fail?

Before choosing the appropriate model, it is critical to understand why models frequently fail to predict clinical results.

Limited predictive validity

A lot of old models, especially those that include animals, don't adequately show how human disease works. Variations in genetics, physiology, and immunological responses may result in inconsistencies between preclinical and clinical outcomes. This is particularly true in cancer and central nervous system (CNS) illnesses.

Oversimplified disease representation

Conventional in vitro systems, such as 2D cell cultures, are not as complicated as human tissues. They frequently fail to capture important aspects such as tumor microenvironment, immunological interactions, and cellular heterogeneity.

Reproducibility Issues

Variability in experimental design, model handling, and data interpretation has exacerbated the reproducibility dilemma in preclinical research. Irreproducible discoveries erode trust in model-based forecasts.

Lack of human-relevant biology

Species differences remain a major restriction. Critical aspects like target expression, signaling pathways, and metabolic processes might vary dramatically across model systems and people.

Key takeaway: Successful drug development depends not only on using models, but on selecting the right models for the right purpose.

In Vitro vs In Vivo vs Emerging Models

Emerging Human-Relevant Models

Recent advances have introduced more physiologically relevant systems:

• Organoids: Patient-derived 3D structures that preserve tissue architecture
• Organ-on-chip systems: Microfluidic platforms that mimic organ-level functions
• Microphysiological systems (MPS): Integrated platforms for multi-organ interaction

These models are increasingly viewed as a bridge between traditional in vitro systems and clinical studies.

A Step-by-Step Drug Model Selection Framework

A Framework for Choosing Drugs Step by Step

Step 1: Define the context of use

What to do: Make sure your study's purpose is clear.

• Target validation: Make sure that your pharmacological target is important for the biology of the disease.
• Efficacy assessment: Find out if the candidate drugs have the desired impact.
• Safety/toxicity testing: Find any possible off-target effects or organ-specific toxicity.

Step 2: Map the biology of the disease

What to do: Identify key features of the disease relevant to your drug.

• Genetic mutations or markers
• Pathophysiological pathways
• Immune system involvement

Tool: Use disease databases, human tissue transcriptomics, or literature studies to find biological markers that are important.

Hint: Make sure your models include all of the important processes that your medicine is supposed to affect.

Step 3: Make sure the model fits the drug modality

• Small molecules: Usually work well with both in vitro and in vivo pharmacology models. Concentrate on metabolic pathways and the processes of absorption, distribution, metabolism, and excretion (ADME).
• Biologics (antibodies, peptides): Require a model that can respond with more than one target or systems that are based on humans. Check the expression of the target in each species.
• Cell and gene therapies rely on improved translational models (such humanized mice and organoids) to make sure they are effective and are safe.

Tip: Don't use a model if the drug's target isn't compatible with the species.

Step 4: Check the relevance of the translation

Things to check:

• Biomarkers are quantifiable in both models and humans.
• Physiological or behavioral outcomes that are important for clinical practice
• PK/PD interactions that can be modeled or extended to humans

Hit: Choose models where the endpoints may be connected to predicted clinical outcomes in a quantifiable way.

Step 5: Use a strategy with more than one model

Why: No single model can encompass all elements of disease biology.

How:

1. Conduct first in vitro screening to assess mechanism of action and potency.
2. Secondary in vivo validation: Assess effectiveness within a whole organism environment.
3. A translational human-relevant model: Use organoids, organ-on-chip, or humanized animals to check the predictions.

Tip: List the insights gleaned from each model. Use models that work well together to fill in the blanks and lower the risk of translation.

Step 6: Integrate Data to Make Decisions

Quantitative approaches:

• Model-informed drug development (MIDD)
• Quantitative systems pharmacology (QSP)

Action: Use mechanistic, PK/PD, and effectiveness data from different models to help you decide whether to move on or not.

Tip: Use computer modeling to figure out which preclinical results are most likely to lead to human consequences.

Step 7: Things to Think About in Real Life

• Availability of validated models
• Throughput and study duration
• Cost constraints
• Ethical and regulatory requirements

Tip: Find a balance between scientific accuracy and practical use, especially when early-stage screening.

The Selection of Models Based on Therapeutic Area

Common models used in oncology

• Cell line-derived xenografts (CDX) are a method that allows for rapid and reproducible examinations of tumor progression.
• By preserving the heterogeneity of human tumors, patient-derived xenografts (PDX) offer improved clinical predictability.
• Immune-competent models that are ideal for immunotherapy are referred to as syngeneic models.

Selection tips:

• Use PDX for lead optimization and translational studies.
• Use syngeneic models to evaluate immune checkpoint inhibitors.
• Consider 3D tumor spheroids for early screening of cytotoxic agents.

Disorders of the Central Nervous System

The primary obstacle is that it is frequently challenging to transfer behavioral objectives to human beings.

Common models:

• Parkinson's disease, Alzheimer's disease, and epilepsy all have rodent models, either hereditary or produced.
• Neurons or organoids produced from human induced pluripotent stem cells for use in mechanistic research.

Advice on the selection process:

• Make use of a mix of behavioral experimentation and neural cultures that are relevant to humans.
• Utilize microfluidic BBB chips or in vivo imaging to confirm the early breach of the blood-brain barrier.

Immunology and the Inflammatory State

Common models:

• Inflammation after an acute event: LPS-induced models
• Inflammation that is ongoing, including arthritis caused by collagen and TNBS colitis
• Immune-targeting medications that are tested on humanized mouse patients

Advice on the selection process:

• Ensure that the immunological route in the model corresponds to the mechanism that your medicine is intended to target.
• It is necessary to verify that the cytokine profiles are in agreement with human illness.

Metabolic Disorders

Common models:

• Diet-induced obesity or type 2 diabetes models
• Genetic knockout or transgenic models

Selection tips:

• Use diet-induced models for environmental/physiological relevance.
• Use genetic models to clarify mechanism of action.
• Combine in vitro hepatocyte or adipocyte systems for metabolic profiling.

Infectious Diseases

Common models:

• Pathogen-specific animal models
• Ex vivo human tissue cultures

Selection tips:

• Prioritize models that replicate key human pathophysiology (e.g., viral tropism, immune response).
• Use organoids or microphysiological systems to reduce animal usage while maintaining translational relevance.

Providing General Direction Across All Therapeutic Domains

• Instead of relying on a single system, you should make use of modeling that is complimentary.
• It is necessary to validate human relevance at each level, including biomarkers, PK/PD, and outcomes.
• For more open and honest decision-making, make sure to document your assumptions and constraints.
• Utilize the knowledge of the CRO in order to have access to specialized models and integrate complicated data in an effective manner

A Final Word

Choosing the appropriate preclinical model is not about identifying a single "best" system. Instead, it necessitates a systematic strategy that incorporates numerous models, fits with research goals, and promotes translational relevance.

As drug development gets more complicated, the emphasis is moving from model selection to overall research plan design. Researchers may dramatically increase the predictive power of preclinical investigations, and hence the effectiveness of clinical translation, by implementing a systematic framework and harnessing new technology.

FAQ

Q1: What is the best way to test drugs before they are used in people?

There is no one best model. The best decision depends on the study goal, the disease area, and the type of medical treatment.

Q2: How can I choose between in vitro and in vivo models?

In vitro models are suitable for early-stage screening and mechanistic research. In vivo models are needed for systemic validation and regulatory studies.

Q3: What are translational models?

Translational models are systems that aim to improve the prediction of human clinical outcomes, frequently employing human-derived tissues or cutting-edge technology.

Q4: Why are preclinical models unable to predict clinical outcomes?

Failures are frequently the result of species differences, simple systems, and a lack of human-relevant biology.

Q5: How many models should be used in investigations before they are done?

A multi-model strategy is suggested to encompass several facets of disease biology and enhance forecasting precision.

Creative Bioarray Relevant Recommendations